ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 134 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.20 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,277,573 | -19.1% | 113,538 | +13.8% | 0.00% | – |
| Q2 2023 | $2,814,060 | +106.3% | 99,754 | +25.8% | 0.00% | – |
| Q1 2023 | $1,363,736 | +54.2% | 79,287 | +80.6% | 0.00% | – |
| Q4 2022 | $884,287 | -64.2% | 43,907 | -61.5% | 0.00% | – |
| Q3 2022 | $2,472,000 | +207.8% | 114,121 | +299.5% | 0.00% | – |
| Q2 2022 | $803,000 | -77.2% | 28,568 | -62.5% | 0.00% | – |
| Q1 2022 | $3,519,000 | -70.1% | 76,266 | -45.4% | 0.00% | – |
| Q4 2021 | $11,750,000 | +26.3% | 139,786 | +0.2% | 0.00% | -100.0% |
| Q3 2021 | $9,300,000 | +276.2% | 139,551 | +200.3% | 0.00% | – |
| Q2 2021 | $2,472,000 | +776.6% | 46,473 | +613.9% | 0.00% | – |
| Q1 2021 | $282,000 | -57.5% | 6,510 | -49.1% | 0.00% | – |
| Q4 2020 | $664,000 | – | 12,784 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Decheng Capital Management III (Cayman), LLC | 2,099,583 | $42,117,635 | 14.06% |
| Mayo Clinic | 187,143 | $3,754,089 | 7.23% |
| Matrix Capital Management Company, LP | 13,959,973 | $280,037,058 | 3.36% |
| 5AM Venture Management, LLC | 490,000 | $9,829,400 | 2.83% |
| Eventide Asset Management | 7,814,039 | $156,749,622 | 2.82% |
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 961,486 | $19,287,410 | 2.70% |
| Avidity Partners Management LP | 2,100,000 | $42,126,000 | 1.70% |
| First Light Asset Management, LLC | 848,477 | $17,020,449 | 1.62% |
| Sofinnova Investments, Inc. | 1,211,641 | $24,305,518 | 1.53% |
| SECTORAL ASSET MANAGEMENT INC | 386,525 | $7,753,692 | 1.51% |